# Ipamorelin vs Sermorelin: Research Comparison of Two GH Secretagogues

> Ipamorelin vs sermorelin compared by mechanism, half-life, and evidence: a ghrelin-receptor GHRP versus a short-acting GHRH analog, why they are complementary classes, and what each is approved for.

A ghrelin-receptor GHRP set beside a GHRH analog — two different mechanisms, two different evidence bases, often paired rather than chosen between.

## The short version

Ipamorelin vs sermorelin is, at heart, a comparison of two different keys to the same lock. Both raise growth hormone, but by different receptors. Ipamorelin is a GHRP — it works on the ghrelin receptor (GHS-R1a) and delivers a clean, selective GH pulse. Sermorelin is a GHRH analog — it mimics the body's own growth-hormone-releasing hormone and works on the GHRH receptor. Because the two mechanisms are complementary, they are more often *combined* than chosen between, the same way ipamorelin is paired with the longer-acting GHRH analog CJC-1295. The biggest practical contrast is regulatory history, not pharmacology: sermorelin has an approved-drug past, while ipamorelin has never been approved anywhere and failed its only human efficacy trial. This page compares mechanism, duration, and evidence, with every figure cited.

## Mechanism — different receptors, complementary actions

Ipamorelin activates the ghrelin / GHS-R1a receptor on pituitary somatotrophs to release GH, and its defining trait is selectivity — no meaningful rise in ACTH, cortisol, or prolactin [1]. Sermorelin acts on the GHRH receptor, the same receptor the body's own GHRH uses. The two are not substitutes at the molecular level: a GHRP and a GHRH analog stimulate GH through distinct, synergistic pathways, which is the whole basis for combining the classes [7]. A neuroendocrine review describes the circuit-level cooperation — ghrelin-receptor agonists suppress somatostatin and amplify GHRH signaling at the pituitary [9]. So ipamorelin vs sermorelin is less a rivalry than a description of two complementary tools.

## Duration and pharmacokinetics

Ipamorelin's terminal half-life in people is about 2 hours, and it produces a single GH pulse peaking near 40 minutes after dosing [2]. Sermorelin is also short-acting — both ipamorelin and sermorelin are short-duration agents compared with the long-acting GHRH analog CJC-1295, which sustained 2- to 10-fold GH elevation for more than six days after a single dose in healthy adults [11]. That contrast in duration is exactly why community protocols tend to pair a short GHRP like ipamorelin with a *longer*-acting GHRH analog rather than with a short one — to combine an acute pulse with a sustained elevation. Note that the CJC-1295 figures come from a study on CJC-1295, not on ipamorelin or sermorelin [11].

## Evidence and regulatory status

The sharpest difference between the two is the evidence and approval history. Ipamorelin has never been approved as a drug anywhere; its only Phase 2 trial, for postoperative ileus, missed its primary endpoint, and it was reviewed by the FDA's Pharmacy Compounding Advisory Committee in 2024 and removed from the interim 503A Category 2 bulk-substances list [3]. Sermorelin, by contrast, has an approved-drug history as a GHRH analog. Both are prohibited in sport under WADA category S2 as growth hormone secretagogues [12]. For a research reader, the takeaway is that "ipamorelin vs sermorelin" compares a never-approved selective GHRP against a GHRH analog with a regulatory track record — different classes, different evidentiary footing.

## Can they be combined

Yes, in principle the classes are combinable — a GHRP and a GHRH analog act synergistically, which is the documented rationale for any GHRH+GHRP pairing [7] [9]. In practice, community stacks more often pair ipamorelin with the *long-acting* GHRH analog CJC-1295 than with the short-acting sermorelin, to get a sustained GHRH-driven elevation alongside the ipamorelin pulse [11]. But the same caveat that governs the [ipamorelin cjc-1295](/with-cjc-1295) stack applies here: no controlled trial has tested any ipamorelin-plus-GHRH-analog combination for an outcome. The synergy is read off single-agent pharmacology, and combination-specific safety and efficacy in humans remain uncharacterized [3].

---

A Carbon-plain reading of the ipamorelin record: the selective GH pulse and the ~2-hour human half-life logged where the studies confirm them, the failed Phase 2 trial and the blank long-term-safety line set in equal type, and the CJC-1295 stack read as class pharmacology rather than a tested product — the word 'safe' here naming a question we keep open, with no clinic behind the page and nothing dosed, compounded, prescribed, or sold.